Assemblyman Kang Ki-yoon Criticizes, "CDC's Remdesivir Import Quantity Is Inappropriate"

Obtained Non-Public Internal Document from KCDC ... Import Decision for Only 5,360 Units

Kang Ki-yoon, member of the United Future Party

[Asia Economy Yeongnam Reporting Headquarters Reporter Hwang Choi Hyun-joo] Kang Ki-yoon, a member of the Future United Party (Changwon Seongsan), announced on the 8th that he obtained an internal document from the Korea Disease Control and Prevention Agency (KDCA) deciding to import 5,360 doses of Remdesivir, a treatment gaining attention for COVID-19.

According to the internal document obtained by Rep. Kang, on the 3rd of last month, KDCA sent an official letter to Gilead Sciences Korea, the manufacturer and producer of Remdesivir, stating that they would import a total of 5,360 doses, including 360 doses for urgent needs and 5,000 doses for pandemic preparedness.

Rep. Kang stated that KDCA received some free supply from Gilead this month and, as of the 6th, supplied Remdesivir to 29 domestic patients, but the exact amount of the supplied doses has not been disclosed.

Starting next month, KDCA plans to purchase Remdesivir through price negotiations with Gilead, aiming to import 5,360 doses.

Rep. Kang criticized, “The U.S. government has declared that all Americans can receive treatment whenever they want. Since it is impossible to specify when the pandemic will end or when explosive infections will suddenly occur domestically, the appropriateness of importing 5,360 doses in terms of scale must be thoroughly reviewed and secured.”

Meanwhile, as of this date, the number of confirmed COVID-19 cases in Korea is 13,244, with 24,012 tests in progress and 285 deaths.

This content was produced with the assistance of AI translation services.